Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patientswith diabetes

Diabetes Care

Volumn 36, Issue 8, 2013, Pages 2211-2216

  Alexopoulos, Dimitrios ^a   Xanthopoulou, Ioanna ^a   Mavronasiou, Eleni ^a   Stavrou, Katerina ^a   Siapika, Argyro ^a   Tsoni, Evropi ^a   Davlouros, Periklis ^a  

^a UNIVERSITY HOSPITAL OF PATRAS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIURETIC AGENT; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; NITRIC ACID DERIVATIVE; ORAL ANTIDIABETIC AGENT; PRASUGREL; PROTON PUMP INHIBITOR; PURINERGIC P2Y12 RECEPTOR; TICAGRELOR; ADENOSINE; ANTITHROMBOCYTIC AGENT; PIPERAZINE DERIVATIVE; THIOPHENE DERIVATIVE; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BLEEDING; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FEMALE; HUMAN; LOADING DRUG DOSE; MALE; PATIENT COMPLIANCE; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; THROMBOCYTE FUNCTION; ANALOGS AND DERIVATIVES; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; MIDDLE AGED; THROMBOCYTE ACTIVATION;

ACUTE CORONARY SYNDROME; ADENOSINE; AGED; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PIPERAZINES; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; SINGLE-BLIND METHOD; THIOPHENES; TICLOPIDINE;

EID: 84881339079     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-2510     Document Type: Article

References (23)

1. Roffi M, Topol EJ. Percutaneous coronary intervention in diabetic patients with non-ST-segment elevation acute coronary syndromes. Eur Heart J 2004;25:190-198
2. Stuckey TD, Stone GW, Cox DA, et al.; CADILLAC investigators. Impact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acutemyocardial infarction (the CADILLAC trial). Am J Cardiol 2005; 95:1-7
3. James S, Angiolillo DJ, Cornel JH, et al.; PLATO Study Group. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J 2010;31:3006-3016
4. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 2005; 54:2430-2435
5. Ferroni P, Basili S, Falco A, Davì G. Platelet activation in type 2 diabetes mellitus. J Thromb Haemost 2004;2:1282-1291
6. Geisler T, Anders N, Paterok M, et al. Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation. Diabetes Care 2007;30:372-374
7. Serebruany V, Pokov I, Kuliczkowski W, Chesebro J, Badimon J. Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease. Thromb Haemost 2008;100:76-82
8. Ferreiro JL, Angiolillo DJ. Diabetes and antiplatelet therapy in acute coronary syndrome. Circulation 2011;123:798-813
9. Wiviott SD, Braunwald E, McCabe CH, et al.; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-2015
10. Wallentin L, Becker RC, Budaj A, et al.; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361: 1045-1057
11. Angiolillo DJ, Badimon JJ, Saucedo JF, et al. A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial. Eur Heart J 2011;32:838-846
12. Wiviott SD, Braunwald E, Angiolillo DJ, et al.; TRITON-TIMI 38 Investigators. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation 2008;118:1626-1636
13. Cannon CP, Harrington RA, James S, et al.; PLATelet inhibition and patient Outcomes Investigators. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet 2010; 375:283-293
14. Saucedo JF. Antiplatelet therapy for patients with diabetes mellitus and acute coronary syndrome. Prim Care Diabetes 2012;6:167-177
15. Alexopoulos D, Galati A, Xanthopoulou I, et al. Ticagrelor versus prasugrel in acute coronary syndrome patientswith high onclopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study. J Am Coll Cardiol 2012;60:193-199
16. Alexopoulos D, Xanthopoulou I, Gkizas V, et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv 2012;5:797-804
17. AlexopoulosD, Xanthopoulou I, Davlouros P, et al. Prasugrel overcomes high onclopidogrel platelet reactivity in chronic coronary artery disease patients more effectively than high dose (150 mg) clopidogrel. Am Heart J 2011;162:733-739
18. Brar SS, ten Berg J, Marcucci R, et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. J Am Coll Cardiol 2011;58:1945-1954
19. Cuisset T, Gaborit B, Dubois N, et al. Platelet reactivity in diabetic patients undergoing coronary stenting for acute coronary syndrome treated with clopidogrel loading dose followed by prasugrel maintenance therapy. Int J Cardiol. 16 October 2012 [Epub ahead of print]
20. Flierl U, Schöpp C, Jaitner J, Bauersachs J, Schäfer A. The novel P2Y 12 antagonist AZD6140 rapidly and reversibly reduces platelet activation in diabetic rats. Thromb Res 2010;125:e93-e99
21. Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 2009;120:2577-2585
22. Roe MT, Armstrong PW, Fox KA, et al.; TRILOGY ACS Investigators. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med 2012;367:1297-1309
23. Collet JP, Cuisset T, Rangé G, et al.; ARCTIC Investigators. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 2012;367: 2100-2109